Names | |
---|---|
IUPAC name 2-[Methyl-[(E)-3-phenylprop-2-enyl]amino]-1-phenylpropan-1-ol | |
Identifiers | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.001.838 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
Properties | |
C19H23NO | |
Molar mass | 281.399 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Cinnamedrine (INN, USAN), also known as N-cinnamylephedrine, is a sympathomimetic drug with similar effects relative to those of ephedrine. [1] [2] It also has some local anesthetic activity. [2] Cinnamedrine was previously used, in combination with analgesics, as an antispasmodic to treat dysmenorrhea in the over-the-counter drug Midol in the 1980s. [2] [3] There is a case report of the drug being abused as a psychostimulant. [4]
Boldenone, is a naturally occurring anabolic–androgenic steroid (AAS) and the 1(2)-dehydrogenated analogue of testosterone. Boldenone itself has never been marketed; as a pharmaceutical drug, it is used as boldenone undecylenate, the undecylenate ester.
Fluorometholone, also known as 6α-methyl-9α-fluoro-11β,17α-dihydroxypregna-1,4-diene-3,20-dione, is a synthetic glucocorticoid which is used in the treatment of inflammatory eye diseases. The C17α acetate ester, fluorometholone acetate, is also a glucocorticoid and is used for similar indications.
Thozalinone (USAN) is a psychostimulant that has been used as an antidepressant in Europe. It has also been trialed as an anorectic. Thozalinone is described as a "dopaminergic stimulant", and likely acts via inducing the release of dopamine and to a minimal extent norepinephrine; similar to analogue pemoline, it is seemingly devoid of abuse potential unlike common psychostimulants that increase catecholamines.
Embutramide is a potent opioid analgesic and sedative drug that is structurally related to methadone. It was developed by Hoechst A.G. in 1958 and was investigated as a general anesthetic agent, but was found to have a very narrow therapeutic window, with a 50 mg/kg dose producing effective sedation and a 75 mg/kg dose being fatal. Along with strong sedative effects, embutramide also produces respiratory depression and ventricular arrhythmia. Because of these properties, it was never adopted for medical use as an anesthetic as it was considered too dangerous for this purpose. Instead it is used for euthanasia in veterinary medicine, mainly for the euthanization of dogs.
Prednimustine, sold under the brand names Mostarina and Sterecyst, is a medication which is used in chemotherapy in the treatment of leukemias and lymphomas. It is the ester formed from two other drugs, prednisolone and chlorambucil. Rarely, it has been associated with myoclonus.
Formebolone, also known as formyldienolone, as well as 2-formyl-11α-hydroxy-17α-methyl-δ1-testosterone, is an orally active anabolic-androgenic steroid (AAS) described as an anticatabolic and anabolic drug that is or has been marketed in Spain and Italy. As an AAS, it shows some anabolic activity, though it is inferior to testosterone in terms of potency, but is said to have virtually no androgenic activity. Formebolone counteracts the catabolic effects of potent glucocorticoids like dexamethasone phosphate. A close analogue, roxibolone, shows similar antiglucocorticoid activity to formebolone but, in contrast, is devoid of activity as an AAS.
Oxymesterone, also known as methandrostenediolone, as well as 4-hydroxy-17α-methyltestosterone or 17α-methylandrost-4-en-4,17β-diol-3-one, is an orally active anabolic-androgenic steroid (AAS). It was known by 1960.
Norclostebol is a synthetic androgen and anabolic steroid (AAS) that was derived from nandrolone. It was described in the literature in 1957. Norclostebol is also used as an ester, norclostebol acetate.
Chloral betaine, also known as cloral betaine (INN), is a sedative-hypnotic drug. It was introduced by Mead Johnson in the United States in 1963. It is a betaine complex with chloral hydrate, which acts as an extended-acting formulation of chloral hydrate which is then metabolized into trichloroethanol, which is responsible for most or all of its effects.
Butidrine (INN), or butedrine or butydrine, also known as hydrobutamine or idrobutamine, is a beta blocker related to pronethalol and propranolol that was developed in the 1960s. Similarly to certain other beta blockers, butidrine also possesses local anesthetic properties.
Doisynoestrol, also known as fenocycline, as well as cis-bisdehydrodoisynolic acid 7-methyl ether, is a synthetic nonsteroidal estrogen of the doisynolic acid group that is no longer marketed. It is a methyl ether of bisdehydrodoisynolic acid. Doisynoestrol was described in the literature in 1945. It has about 0.02% of the relative binding affinity of estradiol for the estrogen receptor.
LS-1727 is a synthetic, injected anabolic–androgenic steroid (AAS) and a nitrosocarbamate ester of nandrolone (19-nortestosterone) which was developed as a cytostatic antineoplastic agent but was never marketed.
Norclostebol acetate, or norchlorotestosterone acetate (NClTA), also known as 4-chloro-19-nortestosterone 17β-acetate or as 4-chloroestr-4-en-17β-ol-3-one, is a synthetic, injectable anabolic-androgenic steroid (AAS) and derivative of 19-nortestosterone (nandrolone). It is an androgen ester – specifically, the C17β acetate ester of norclostebol (4-chloro-19-nortestosterone).
Clostebol acetate (BAN), also known as 4-chlorotestosterone 17β-acetate (4-CLTA) or as 4-chloroandrost-4-en-17β-ol-3-one 17β-acetate, is a synthetic, injected anabolic-androgenic steroid (AAS) and a derivative of testosterone that is marketed in Germany and Italy. It is an androgen ester – specifically, the C17β acetate ester of clostebol (4-chlorotestosterone) – and acts as a prodrug of clostebol in the body. Clostebol acetate is administered via intramuscular injection.
Clomifenoxide (INN), also known as clomifene N-oxide, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is described as an antiestrogen and "gonad stimulant" and was never marketed. It is an active metabolite of clomifene.
Androstenediol dipropionate, or 5-androstenediol 3β,17β-dipropionate, also known as androst-5-ene-3β,17β-diol 3β,17β-dipropionate, is a synthetic anabolic–androgenic steroid and an androgen ester – specifically, the dipropionate diester of 5-androstenediol (androst-5-ene-3β,17β-diol) – which has been marketed in Europe, including in Spain, Italy, and Austria.
Spiroxasone is a synthetic, steroidal antimineralocorticoid of the spirolactone group which was developed as a diuretic and antihypertensive agent but was never marketed. It was synthesized and assayed in 1963. The drug is 7α-acetylthiospirolactone with the ketone group removed from the C17α spirolactone ring. Similarly to other spirolactones like spironolactone, spiroxasone also possesses antiandrogen activity.
Dacuronium bromide is an aminosteroid neuromuscular blocking agent which was never marketed. It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).
Cortobenzolone, also known as betamethasone salicylate, is a synthetic glucocorticoid corticosteroid and corticosteroid ester which is marketed in Spain.